- Showcases Oligio X, Lavieen, and TIGHTAN through booth exhibitions and live demonstration sessions from January 29 (Thu) to 31 (Sat)
- Hosts a seminar and networking program for approximately 150 participants on January 30 (Fri) at The Peninsula Paris
- Explores practical collaboration opportunities with medical professionals from around the world while accelerating its expansion strategy into Europe and the Middle East
(January 26, 2026) WONTECH Co., Ltd. (KOSDAQ: 336570), a laser and energy-based medical solutions company led by CEOs Kim Jong-won and Kim Jung-hyun, will participate in IMCAS World Congress 2026, taking place from January 29 (Thu) to 31 (Sat) at the Palais des Congrès in Paris, France. Through the event, the company aims to expand academic exchange and strengthen partnerships with medical professionals worldwide.
IMCAS (International Master Course on Aging Science) is the world’s largest academic congress in dermatology, plastic surgery, and aesthetic medicine, bringing together medical professionals from more than 130 countries along with leading global medical device companies. The annual event serves as a platform for sharing the latest clinical trends and technological advancements while setting global standards in the medical aesthetics field.
At the event, WONTECH will showcase its flagship product lineup including Oligio X, Lavieen, and TIGHTAN, while hosting demonstration sessions that allow medical professionals to experience the operating principles and treatment processes of the devices firsthand. Products from its subsidiary WonMedico will also be displayed.
During IMCAS, WONTECH will also host a seminar and networking program on January 30 (Fri) at The Peninsula Paris, bringing together approximately 150 physicians and partners from Europe, Asia, and the Middle East. Building on the collaborative relationships established during last year’s seminar, many of which have since developed into tangible business partnerships, the company has significantly expanded the scale of this year’s event.
The seminar will go beyond a simple product introduction, serving as an academic exchange platform titled “MASTER’S CLASS in Paris,” where global medical professionals will share treatment experiences and market application strategies based on real clinical data.
In the program, Dr. Seunghyun Kim (Fine Clinic, Korea) will present “Clinical Outcomes of Oligio in Real Practice,” highlighting procedure satisfaction and patient responses observed in clinical settings. Dr. Chaloemchai Sriakkrapong (Thailand) will introduce an “Anatomy-Based RF Contouring Protocol Using Oligio X,” while Dr. Joanna Gralinska Wyrebska (Poland) will discuss the clinical expansion potential of Lavieen through “Whole-Body Clinical Application Cases.” The session will conclude with Dr. Seungmin Oh (O& Clinic, Korea), who will present on “Optimization and Revenue Maximization Strategies with Oligio X.”
* MASTER'S CLASS in Paris
Following the presentations, a networking session will be held, allowing speakers and participants to engage in open discussions and exchange insights on regional clinical trends and market dynamics.
A WONTECH official stated, “This year’s IMCAS will serve as both a strategic foothold for expanding into the European and Middle Eastern markets and an important turning point in WONTECH’s global expansion.” The official added that, with recent regulatory approvals secured for key products in markets including the United Kingdom, Australia, the United States, and Saudi Arabia, the company plans to leverage the event to explore practical collaboration opportunities with physicians worldwide and accelerate its entry strategy for Europe and the Middle East.
The official further noted, “Building on our proven technology and accumulated clinical experience, we will continue strengthening trust in the global market.”
- Hosts a seminar and networking program for approximately 150 participants on January 30 (Fri) at The Peninsula Paris
- Explores practical collaboration opportunities with medical professionals from around the world while accelerating its expansion strategy into Europe and the Middle East
▲ Image of WONTECH Co., Ltd. Participating in IMCAS World Congress 2026
(January 26, 2026) WONTECH Co., Ltd. (KOSDAQ: 336570), a laser and energy-based medical solutions company led by CEOs Kim Jong-won and Kim Jung-hyun, will participate in IMCAS World Congress 2026, taking place from January 29 (Thu) to 31 (Sat) at the Palais des Congrès in Paris, France. Through the event, the company aims to expand academic exchange and strengthen partnerships with medical professionals worldwide.
IMCAS (International Master Course on Aging Science) is the world’s largest academic congress in dermatology, plastic surgery, and aesthetic medicine, bringing together medical professionals from more than 130 countries along with leading global medical device companies. The annual event serves as a platform for sharing the latest clinical trends and technological advancements while setting global standards in the medical aesthetics field.
At the event, WONTECH will showcase its flagship product lineup including Oligio X, Lavieen, and TIGHTAN, while hosting demonstration sessions that allow medical professionals to experience the operating principles and treatment processes of the devices firsthand. Products from its subsidiary WonMedico will also be displayed.
During IMCAS, WONTECH will also host a seminar and networking program on January 30 (Fri) at The Peninsula Paris, bringing together approximately 150 physicians and partners from Europe, Asia, and the Middle East. Building on the collaborative relationships established during last year’s seminar, many of which have since developed into tangible business partnerships, the company has significantly expanded the scale of this year’s event.
The seminar will go beyond a simple product introduction, serving as an academic exchange platform titled “MASTER’S CLASS in Paris,” where global medical professionals will share treatment experiences and market application strategies based on real clinical data.
In the program, Dr. Seunghyun Kim (Fine Clinic, Korea) will present “Clinical Outcomes of Oligio in Real Practice,” highlighting procedure satisfaction and patient responses observed in clinical settings. Dr. Chaloemchai Sriakkrapong (Thailand) will introduce an “Anatomy-Based RF Contouring Protocol Using Oligio X,” while Dr. Joanna Gralinska Wyrebska (Poland) will discuss the clinical expansion potential of Lavieen through “Whole-Body Clinical Application Cases.” The session will conclude with Dr. Seungmin Oh (O& Clinic, Korea), who will present on “Optimization and Revenue Maximization Strategies with Oligio X.”
* MASTER'S CLASS in Paris
| Speaker | Product | Subject |
| Dr. Seung hyun Kim (Korea) |
Oligio | From Hesitation to High Satisfaction: How Oligio Actually Performs in Practice |
| Dr. Chaloemchai Sriakkrapong (Thailand) |
Oligio X | When Anatomy Meets Energy: The X-Layer Protocol for Facial RF Contouring |
| Dr. JOANNA GRALINSKA WYREBSKA (Poland) |
Lavieen | Full-Body Clinical Applications from Head to Toe |
| Dr. Seung min Oh (Korea) |
Oligio X | Oligio X Optimization and Revenue Maximization Strategy |
Following the presentations, a networking session will be held, allowing speakers and participants to engage in open discussions and exchange insights on regional clinical trends and market dynamics.
A WONTECH official stated, “This year’s IMCAS will serve as both a strategic foothold for expanding into the European and Middle Eastern markets and an important turning point in WONTECH’s global expansion.” The official added that, with recent regulatory approvals secured for key products in markets including the United Kingdom, Australia, the United States, and Saudi Arabia, the company plans to leverage the event to explore practical collaboration opportunities with physicians worldwide and accelerate its entry strategy for Europe and the Middle East.
The official further noted, “Building on our proven technology and accumulated clinical experience, we will continue strengthening trust in the global market.”